{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Abbreviation Term', 'Description', 'FSH', 'follicle-stimulating hormone', 'GCP', 'Good Clinical Practice', 'GGT', 'gamma-glutamyl transferase', 'GINA', 'Global Initiative for Asthma', 'HAC', 'Hepatology Assessment Committee', 'HBcAb', 'Hepatitis B core antibody', 'HBsAg', 'Hepatitis B surface antigen', 'hCG', 'human chorionic gonadotropin', 'HDPE', 'high-density polyethylene', 'HIV', 'human immunodeficiency virus', 'HIPAA', 'Health Insurance Portability and Accountability Act', 'HRT', 'hormonal replacement therapy', 'IB', \"Investigator's Brochure\", 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonisation', 'IDMC', 'Independent Data Monitoring Committee', 'IEC', 'Independent Ethics Committee', 'IL', 'interleukin (IL-4, IL-5, IL-13)', 'ILC2', 'Group 2 innate lymphoid cells', 'INCS', 'intranasal corticosteroids', 'INR', 'international normalized ratio', 'IP', 'investigational product', 'IRB', 'Institutional Review Board', 'IRT', 'Interactive Response Technology', 'ITT', 'intent-to-treat', 'IUD', 'intrauterine device', 'IUS', 'intrauterine hormone-releasing system', 'LAM', 'lactational amenorrhoea method', 'LDH', 'lactate dehydrogenase', 'LXA4', 'lipoxin A4', 'MCID', 'minimal clinically important difference', 'MFNS', 'mometasone furoate nasal spray', '81', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Abbreviation Term', 'Description', 'MMRM', 'mixed-effects model with repeated measures', 'NAFLD', 'non-alcoholic fatty liver disease', 'NC', 'nasal congestion', 'nNO', 'nasal nitric oxide', 'NP', 'nasal polyps', 'NPS', 'nasal polyp score', 'OC', 'osteomeatal complex', 'PD', 'pharmacodynamic', 'PGD2', 'prostaglandin D2', 'PGE2', 'prostaglandin E2', 'PGx', 'pharmacogenetics', 'PK', 'pharmacokinetic', 'QD', 'once daily', 'QTcF', \"Fridericia's correction formula for QT interval (interval between\", 'wave', 'and T wave)', 'RBC', 'red blood cell', 'REML', 'restricted maximum-likelihood', 'RNA', 'ribonucleic acid', 'SAE', 'serious adverse event', 'SNOT-22', 'Sino-Nasal Outcome Test', 'SoA', 'schedule of activities', 'SOC', 'standard of care', 'SUSAR', 'suspected unexpected serious adverse reaction', 'TEAE', 'treatment-emergent adverse event', 'Th2', 'T Helper cell type 2', 'TSS', 'total symptom score', 'ULN', 'upper limit of normal', 'UPSIT', 'University of Pennsylvania Smell Identification Test', 'VAS', 'visual analog scale', 'WBC', 'white blood cell', 'WOCBP', 'women of childbearing potential', '82', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '10.13.', 'Appendix 13: Protocol Amendment History', 'The Protocol Amendment Summary of Changes Table for the current amendment is located', 'directly before the Table of Contents (TOC).', 'DOCUMENT HISTORY', 'Document', 'Date', 'Amendment 4 (v4.0)', '18 Feb 2020', 'Amendment 3 (v3.0)', '28 Aug 2019', 'Amendment 2 (v2.1)', '02 May 2019', 'Amendment 1 (v2.0.0)', '05 Apr 2019', 'Original Protocol (v1.0.0)', '24 Jan 2019', 'Amendment 4 (v4.0; 18 Feb 2020)', 'This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of', 'Directive 2001/20/EC of the European Parliament and the Council of the European Union.', 'Overall Rationale for the Amendment:', 'The primary purpose of this amendment is to enhance monitoring of liver parameters during the', 'conduct of the trial and provide clarification on eligibility criteria.', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 1.3 Schedule of', 'Addition of a Week 1 visit (Visit', 'Week 1 visit was added to', 'Activities;', '2.5) serum chemistry panel', 'enhance laboratory monitoring', 'Section 1.2 Schema', 'following Randomization (Visit', 'during the first month following', '2). Added CRS exacerbation', 'IP initiation. Clarified that CRS', 'review at Visits 1, 2, and 2.5.', 'exacerbation review is performed', 'at every visit.', 'Section 4.1.1 Study Design;', 'Added visual examination as a', 'Clarified definition of absence of', 'Section 4.2.1 Study', 'method of confirming absence of', 'nasal polyps', 'Population;', 'nasal polyps', 'Section 6.3.1 Randomization', 'Section 5.3', 'Modification of the', 'Enhance safety characterization', 'Randomization Criteria #6', 'randomization criteria from ALT', 'of the study population', 'and AST < 2 X ULN to ALT and', 'AST VI 1 X ULN', 'Section 6.3.4 Unblinded', 'Added new monitoring guidelines', 'To enable unblinded medical', 'Sponsor Medical Monitor', 'monitoring of liver and other', 'laboratory parameters of interest', 'by a designated Sponsor Medical', 'Monitor in order to protect', 'subject safety', 'Section 10.3.3 Adverse', 'Updated language describing', 'Clarified definition of adverse', 'Events of Interest', 'adverse events of interest', 'events of interest', '83', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}